PRINCETON, N.J.--(BUSINESS WIRE)--PharmaNet Development Group, Inc., (the “Company”) (NASDAQ: PDGI), announced today that it is updating its 2008 full year earnings guidance primarily due to the postponement and cancellation of certain of the Company’s ongoing clinical development projects in the late stage segment and a lower than expected sample volume of business in the early stage segment.
